In the first data sets we illustrate the methodology on the gene expression measurement results of identical RNA preparations for two commercially available microarray platforms, namely, Affymerix (25-mer), and Amersham (30-mer) [ 14].
Unfortunately none of these studies are directly applicable to one of the most commonly used human transcriptomic microarray platforms, namely Affymetrix Gene 1.0 ST arrays, either because they do not use a random priming approach or because the design of the microarray platform differs substantially from Gene 1.0 ST arrays.
Recently, another human microarray chip based on the Affymetrix Genechip platform – namely the Breast Cancer DSA – was developed by Almac Diagnostics [ 18].
Here we introduce a new, fast, inexpensive method for direct random-primed fluorescent labeling of eukaryotic cDNA for gene expression analysis and compare the results obtained on the NimbleGen microarray platform with two other widely-used labeling methods, namely the NimbleGen-recommended double-stranded cDNA protocol and the indirect (aminoallyl) method.
We have now used a specific approach based on a microarray platform aimed at distinguishing point mutants within an important determinant of antigenicity and host cell tropism, namely the G-H loop of capsid protein VP1.
A specific approach based on a microarray platform aimed at distinguishing point mutants within an important determinant of antigenicity and host cell tropism, namely the G-H loop of capsid protein VP1, was developed.
Then select the microarray platform and specific experiment to search against and the display format.
The accumulated transcribed sequences could be directly used to develop microarray platform.
The design, construction and application of a Pinus microarray platform are described.
After entering a list of genes or microarray element IDs into the ROAD, the user can then select the microarray platform and specific experiment to search against (Figure1a).
